Amgen Inc (AMGN) Gets a Buy Rating from Mizuho Securities
Mizuho Securities analyst Salim Syed assigned a Buy rating to Amgen Inc (AMGN) today and set a price target of $208. The company’s shares opened today at $188.46.
According to TipRanks.com, Syed is a 4-star analyst with an average return of 4.2% and a 58.7% success rate. Syed covers the Healthcare sector, focusing on stocks such as Unity Biotechnology Inc, Atara Biotherapeutics, and Wave Life Sciences.
Amgen Inc has an analyst consensus of Moderate Buy, with a price target consensus of $215.58, a 14.4% upside from current levels. In a report released yesterday, BMO Capital also initiated coverage with a Buy rating on the stock with a $228 price target.
See today’s analyst top recommended stocks >>
Based on Amgen Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $6.2 billion and net profit of $1.93 billion. In comparison, last year the company earned revenue of $5.83 billion and had a GAAP net loss of $4.26 billion.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.